Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Completed · Phase 1
Conditions studied: Relapsed Multiple Myeloma, End-stage Renal Disease
In brief
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with normal kidney function and those with end-stage renal disease to see if they respond differently to the study drug.
Key facts
- Study ID
- NCT01949532
- Run by
- Amgen
- People needed
- 26
- Starts
- 2014-01-01
- Expected to finish
- 2017-01-01
- Last updated by the study team
- 2017-05-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Karmanos Cancer Institute — Detroit, Michigan, United States
- North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital — Lake Success, New York, United States
- Gabrail Cancer Center — Canton, Ohio, United States
- Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic — Nashville, Tennessee, United States
- Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
- UT Southwestern Medical Center — Dallas, Texas, United States
- Royal Prince Alfred Hospital — Camperdown, New South Wales, Australia
- Royal Brisbane and Women's Hospital — Herston, Queensland, Australia
- Monash Health, Monash Medical Centre — Clayton, Victoria, Australia
- St. Vincent's Hospital Melbourne — Fitzroy, Victoria, Australia
- The Alfred Hospital, Malignant Haematology and Stem Cell Transplant Department — Melbourne, Victoria, Australia
- QEII Health Sciences Centre — Halifax, Nova Scotia, Canada
- Sir Mortimer B. Davis-Jewish General Hospital — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.